Efficacy and Safety of a Potent and Selective Peroxisome Proliferator Activated Receptor Alpha Agonist in Subjects With Dyslipidemia and Type 2 Diabetes Mellitus
- 15 August 2008
- journal article
- research article
- Published by Elsevier BV in The American Journal of Cardiology
- Vol. 102 (4), 434-439
- https://doi.org/10.1016/j.amjcard.2008.03.076
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- Effects of a Potent and Selective PPAR-α Agonist in Patients With Atherogenic Dyslipidemia or HypercholesterolemiaJAMA, 2007
- Differential regulation of the cynomolgus, human, and rat acyl-CoA oxidase promoters by PPARαGene, 2006
- Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trialThe Lancet, 2005
- Troponin: the biomarker of choice for the detection of cardiac injuryCMAJ : Canadian Medical Association Journal, 2005
- Peroxisome Proliferator-Activated Receptor Agonists Modulate Heart Function in Transgenic Mice with Lipotoxic CardiomyopathyJournal of Pharmacology and Experimental Therapeutics, 2005
- Multicenter Analytical Evaluation of an Enzymatic Method for the Measurement of Plasma Homocysteine and Comparison with HPLC and ImmunochemistryClinical Chemistry, 2004
- Diabetes, Plasma Insulin, and Cardiovascular DiseaseArchives of Internal Medicine, 2002
- The cardiac phenotype induced by PPARα overexpression mimics that caused by diabetes mellitusJCI Insight, 2002
- Effects of fenofibrate and gemfibrozil on plasma homocysteineThe Lancet, 2001
- Relation of Gemfibrozil Treatment and Lipid Levels With Major Coronary EventsJAMA, 2001